Background
==========

Lower respiratory tract infections are the cause of septic shock in 25% of patients. Telithromycin (TEL), the first ketolide antibiotic, is used for treatment of respiratory infections. TEL is a semisynthetic derivative of the macrolide erythromycin. Beyond their antimicrobial activity, macrolides display immunomodulatory effects, including the inhibition of inflammatory reactions. In the present study, we demonstrate the anti-inflammatory effects of TEL on a septic shock model and a respiratory inflammation model in mice.

Materials and methods
=====================

TEL was a gift from Aventis Pharma (Neuville-sur-Saonc, France). Lipopolysaccharide (LPS) from *Escherichia coli*O26:B6 was purchased from Sigma Chemical Co. (St Louis, MO, USA). BALB/c female mice (10--12 weeks old) were maintained in the facilities of the University of Granada. To induce septic shock, mice were injected intraperitoneally with a dose of 50 mg LPS/kg body weight. To induce respiratory inflammation, mice were exposed for 20 minutes to aerosolized LPS (500 μg/ml saline) in a chamber connected to an air nebulizer (Miko, CA-MI s.n.c., Italy). To investigate the effects of TEL, mice received a single dose of 20 mg ketolide/kg body weight by intraperitoneal injection, 1 hour prior to the administration of LPS. Heparinized blood samples were centrifuged, and plasma was stored at -20°C until cytokine determination. To obtain bronchoalveolar lavage (BAL) fluids, the lungs were lavaged with 1 ml phosphate-buffered saline through an intratracheal catheter. Enzyme immunoassays kits were use to determine TNFα (Pierce Endogen, Rockford, IL, USA) and macrophage inflammatory peptide 2 (MIP-2) (R&D Systems, Minneapolis, MN, USA). The differences in cytokine levels were analyzed using Student\'s *t*test. *P*\< 0.05 was considered significant.

Results
=======

When mice were intraperitoneally challenged with a lethal dose of LPS, TEL protected 50% of animals and significantly reduced the plasma levels of TNFα at 2 hours after LPS administration. In the respiratory inflammation model, the treatment with TEL significantly reduced the BAL levels of TNFα and MIP-2 at 4 hours post endotoxin (Table [1](#T1){ref-type="table"}).

###### 

Effect of telithromycin on cytokine levels in bronchoalveolar lavage and plasma in a mouse respiratory inflammation model

  Treatment   TNFα in BAL (pg/ml)   MIP-2 in BAL (pg/ml)   MIP-2 in plasma (pg/ml)
  ----------- --------------------- ---------------------- -------------------------
  None        11 ± 6                41 ± 3                 1 ± 4
  TEL         9 ± 4                 28 ± 2                 0 ± 0
  LPS         2846 ± 369            1637 ± 254             40 ± 10
  TEL + LPS   1279 ± 285^a^         1020 ± 240^b^          24 ± 5^c^

^a^*P*\< 0.005, significantly different from mice treated with LPS alone.

^b^*P*\< 0.001, significantly different from mice treated with LPS alone.

^c^*P*\< 0.05, significantly different from mice treated with LPS alone.

Conclusion
==========

TEL exerts anti-inflammatory activity *in vivo*that may contribute to its pharmacological effectiveness in the treatment of respiratory infections and their possible progression to septic shock.
